FY2029 EPS Estimate for GH Research Increased by Analyst

GH Research PLC (NASDAQ:GHRS - Free Report) - Analysts at HC Wainwright increased their FY2029 EPS estimates for shares of GH Research in a research note issued on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.13 per share for the year, up from their prior estimate of $0.10. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

A number of other equities research analysts have also commented on the company. Stifel Nicolaus increased their price target on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Royal Bank of Canada started coverage on GH Research in a research note on Friday. They issued an "outperform" rating and a $31.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of GH Research in a research report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price target on the stock. Finally, Canaccord Genuity Group lowered their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $30.67.

GH Research Stock Up 6.7 %

NASDAQ:GHRS traded up $0.70 on Thursday, reaching $11.20. The stock had a trading volume of 421,447 shares, compared to its average volume of 162,909. The company has a market capitalization of $582.71 million, a P/E ratio of -14.18 and a beta of 0.94. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50. The stock has a fifty day moving average price of $10.80 and a 200-day moving average price of $9.17.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new position in shares of GH Research during the fourth quarter worth $44,000. Two Sigma Investments LP acquired a new position in GH Research in the fourth quarter valued at about $117,000. Millennium Management LLC bought a new stake in shares of GH Research in the fourth quarter worth about $145,000. AdvisorShares Investments LLC raised its position in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after purchasing an additional 4,806 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).